News
No Results Found
The page you requested could not be found. Try refining your search, or use the navigation above to locate the post.
Plexus Ventures Advises Mabion S.A. in the Out-Licensing of MabionCD20 (Rituximab Biosimilar)
Philadelphia, Pennsylvania - Plexus Ventures is pleased to announce it served as advisor to Mabion S.A. in the out-licensing of Mabion CD20 (Rituximab Biosimilar) European rights to Mylan Ireland Limited. Michael O’Sullivan, Managing Partner of Plexus Ventures’ London...
Plexus Ventures Assists Celon Pharma to Out-License Semi-Exclusive Rights of Generic Advair® Diskus® to Glenmark Pharmaceuticals for 15 countries in Europe
Philadelphia, Pennsylvania - Plexus Ventures announces the successful completion of a recent out-licensing project on behalf of Celon Pharma. Additional details regarding the transaction, taken from Glenmark’s October 23, 2015 press release are included below:...
Events
BIO International Convention - Boston
June 16 – 19, 2025
Click to Schedule a Meeting
CHPI - Frankfurt
October 28 – 30, 2025
Click to Schedule a Meeting
Articles
Nucleic acid delivery: Are you developing what Big Pharma seeks?
Apr 11, 2023
How can we help you?
Plexus Ventures assists with M&A, divestments, licensing, strategic advice and consulting.
Subscribe to
Plexus News
Follow Us
Check out Plexus Ventures and other industry news shared daily.